BioWorld. Link to homepage.
BioWorld
BioWorld Science
BioWorld Asia
Data Snapshots
Biopharma
Medical technology
Infographics: Dynamic digital data analysis
Index insights
NME Digest
Special reports
Infographics: Dynamic digital data analysis
Trump administration impacts
Med-tech outlook 2026
Under threat: mRNA vaccine research
BioWorld at 35
Biopharma M&A scorecard
Bioworld 2025 review
BioWorld MedTech 2025 review
BioWorld Science 2025 review
Women's health
China's GLP-1 landscape
PFA re-energizes afib market
China CAR T
Alzheimer's disease
Coronavirus
More reports can be found here
BioWorld. Link to homepage.
Sign In
Sign Out
My Account
Subscribe
BioWorld - Friday, March 27, 2026
See today's BioWorld
Home
» Cempra in free fall before adcom for its lead antibiotic
To read the full story,
subscribe
or
sign in
.
Cempra in free fall before adcom for its lead antibiotic
Nov. 3, 2016
By
Mari Serebrov
What a difference a few days and an FDA review can make. A week ago, Cempra Inc. (NASDAQ:CEMP) was trading just shy of $24. Wednesday, it closed at $7.30, down 60.9 percent in the company's heaviest day of trading ever.
BioWorld